The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.
Name: Ranolazine
Type: DrugRanolazine
Single Group Assignment
There is one SNP
Inclusion Criteria: - Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene - Corrected QT interval > 460 msec Exclusion Criteria: - Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors) Inclusion Criteria: - Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene - Corrected QT interval > 460 msec Exclusion Criteria: - Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors) Long QT Syndrome Type 3 Syndrome Long QT Syndrome null --- D1790G ---
Inclusion Criteria: - Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene - Corrected QT interval > 460 msec Exclusion Criteria: - Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors) Inclusion Criteria: - Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene - Corrected QT interval > 460 msec Exclusion Criteria: - Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors) Long QT Syndrome Type 3 Syndrome Long QT Syndrome null --- D1790G --- --- D1790G ---